Published in J Pharmacol Exp Ther on June 27, 2006
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov (2009) 6.69
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol (2011) 3.15
Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science (2012) 3.07
Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol (2009) 2.98
Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med (2010) 2.82
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
Remote control of neuronal signaling. Pharmacol Rev (2011) 2.66
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
Activation mechanism of the β2-adrenergic receptor. Proc Natl Acad Sci U S A (2011) 2.53
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A (2008) 2.42
Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol (2009) 2.39
Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci (2010) 2.36
GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci (2007) 2.35
Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol (2007) 2.17
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol (2010) 2.11
Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem (2012) 2.10
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem (2007) 1.91
Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) (2010) 1.90
μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol (2010) 1.83
JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol (2010) 1.79
Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol (2008) 1.78
Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov (2012) 1.75
Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol (2008) 1.68
A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem (2008) 1.66
Signal transduction by protease-activated receptors. Br J Pharmacol (2010) 1.64
Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A (2010) 1.63
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev (2011) 1.61
Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A (2012) 1.57
Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation. Mol Pharmacol (2007) 1.56
Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX. Structure (2011) 1.54
Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther (2008) 1.52
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A (2008) 1.51
Inhibitors paradoxically prime kinases. Nat Chem Biol (2009) 1.50
Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol (2008) 1.49
Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol (2010) 1.49
Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci U S A (2009) 1.48
Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators. J Comput Aided Mol Des (2009) 1.48
Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem (2010) 1.46
PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci (2009) 1.46
Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A (2008) 1.45
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology (2009) 1.45
Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem (2010) 1.45
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol (2009) 1.44
Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol (2012) 1.44
Allosteric sodium in class A GPCR signaling. Trends Biochem Sci (2014) 1.41
Characterization of a prawn OA/TA receptor in Xenopus oocytes suggests functional selectivity between octopamine and tyramine. PLoS One (2014) 1.40
Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol (2010) 1.40
Efficacy of the β₂-adrenergic receptor is determined by conformational equilibrium in the transmembrane region. Nat Commun (2012) 1.40
Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J Biol Chem (2010) 1.40
Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics (2010) 1.39
Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol (2009) 1.38
Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. Biophys J (2007) 1.37
Agonist-selective signaling is determined by the receptor location within the membrane domains. Proc Natl Acad Sci U S A (2008) 1.36
The behavioral pharmacology of hallucinogens. Biochem Pharmacol (2007) 1.35
Evolution-guided discovery and recoding of allosteric pathway specificity determinants in psychoactive bioamine receptors. Proc Natl Acad Sci U S A (2010) 1.32
Exploring a role for heteromerization in GPCR signalling specificity. Biochem J (2011) 1.31
Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology (2010) 1.30
The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology (2010) 1.30
Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol (2009) 1.30
Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci (2010) 1.30
Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci (2007) 1.29
CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Chem Biol (2011) 1.27
The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther (2009) 1.27
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26
Synaptic activity unmasks dopamine D2 receptor modulation of a specific class of layer V pyramidal neurons in prefrontal cortex. J Neurosci (2012) 1.25
Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci Signal (2011) 1.25
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des (2010) 1.24
On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.24
Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. Chem Biol Drug Des (2010) 1.24
Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv (2009) 1.24
Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open. Br J Pharmacol (2007) 1.23
Salvinorin A analogs as probes in opioid pharmacology. Chem Rev (2008) 1.22
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci (2010) 1.21
Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol (2007) 1.21
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol Pharmacol (2009) 1.20
Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem (2010) 1.20
Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol (2011) 1.20
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. J Med Chem (2012) 1.19
Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol (2008) 1.18
mu-Opioid receptor agonists differentially regulate the expression of miR-190 and NeuroD. Mol Pharmacol (2009) 1.18
Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem (2008) 1.17
Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem (2013) 1.17
The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.17
Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology (2008) 1.16
Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci U S A (2011) 1.16
Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther (2008) 1.15
Serotonin 5-HT(2) and 5-HT(1A)-like receptors differentially modulate aggressive behaviors in Drosophila melanogaster. Neuroscience (2008) 1.15
Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol (2011) 1.15
Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology (2008) 1.15
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. IUBMB Life (2010) 1.14
Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br J Pharmacol (2010) 1.13
Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.13
Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol (2012) 1.12
Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. J Pharmacol Exp Ther (2013) 1.12
Ligand-induced modulation of the free-energy landscape of G protein-coupled receptors explored by adaptive biasing techniques. PLoS Comput Biol (2011) 1.12
Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol (2010) 1.11
Predicting new molecular targets for known drugs. Nature (2009) 9.71
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A (2007) 7.96
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov (2009) 6.69
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci U S A (2007) 6.04
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol (2009) 5.83
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest (2011) 5.12
Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron (2009) 4.98
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell (2008) 4.29
Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol (2008) 4.04
Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2007) 4.02
The expanded biology of serotonin. Annu Rev Med (2009) 3.87
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology (2003) 3.78
Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol (2006) 3.76
IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res (2008) 3.76
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Generation of a synthetic memory trace. Science (2012) 3.55
Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci (2010) 3.55
The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science (2004) 3.54
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
Microtubule plus-end-tracking proteins target gap junctions directly from the cell interior to adherens junctions. Cell (2007) 3.52
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev (2005) 3.33
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov (2012) 3.30
Conformational biosensors reveal GPCR signalling from endosomes. Nature (2013) 3.29
A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol (2006) 3.23
Cargo regulates clathrin-coated pit dynamics. Cell (2006) 3.20
Endocrine regulation of male fertility by the skeleton. Cell (2011) 3.20
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature (2011) 3.19
Structure of the human smoothened receptor bound to an antitumour agent. Nature (2013) 3.08
The Concise Guide to PHARMACOLOGY 2013/14: ion channels. Br J Pharmacol (2013) 3.03
Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J (2008) 2.99
Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol (2009) 2.98
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
A nomenclature for ligand-gated ion channels. Neuropharmacology (2008) 2.93
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev (2003) 2.93
SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors. Nat Cell Biol (2011) 2.92
Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem (2002) 2.87
The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci U S A (2009) 2.86
International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev (2002) 2.86
Cyanine fluorophore derivatives with enhanced photostability. Nat Methods (2011) 2.85
Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. Nat Methods (2010) 2.77
IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res (2010) 2.75
The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem (2002) 2.75
The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci (2008) 2.72
Sequence-dependent sorting of recycling proteins by actin-stabilized endosomal microdomains. Cell (2010) 2.67
Remote control of neuronal signaling. Pharmacol Rev (2011) 2.66
Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem (2005) 2.64
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics (2004) 2.55
Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42
Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol (2005) 2.42
Single-molecule dynamics of gating in a neurotransmitter transporter homologue. Nature (2010) 2.41
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell (2002) 2.40
Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A (2005) 2.33
Quantitative information management for the biochemical computation of cellular networks. Sci STKE (2004) 2.32
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov (2007) 2.29
The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol (2013) 2.29
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
Monitoring the function of membrane transport proteins in detergent-solubilized form. Proc Natl Acad Sci U S A (2007) 2.27
The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol (2002) 2.27
Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature (2007) 2.25
Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation. Proc Natl Acad Sci U S A (2009) 2.25
Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord (2007) 2.24
Overview of nomenclature of nuclear receptors. Pharmacol Rev (2006) 2.21
Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. Nat Struct Mol Biol (2010) 2.20
Substrate-modulated gating dynamics in a Na+-coupled neurotransmitter transporter homologue. Nature (2011) 2.18
Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem (2002) 2.14
The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci U S A (2004) 2.10
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
SNX27 mediates PDZ-directed sorting from endosomes to the plasma membrane. J Cell Biol (2010) 2.10
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci (2007) 2.10
Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem (2012) 2.10